Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Clear Street Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $29

Author: Benzinga Newsdesk | October 22, 2025 07:14am
Clear Street analyst Kaveri Pohlman initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announces Price Target of $29.

Posted In: SGMT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist